BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33273854)

  • 1. Development of Mobile Application for Dynamically Monitoring the Risk of Prostate Cancer and Clinicopathology.
    Wang H; Chen L; Zhou J; Tai S; Liang C
    Cancer Manag Res; 2020; 12():12175-12184. PubMed ID: 33273854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new predictor is comparable to the updated nomogram in predicting the intermediate- and high-risk prostate cancer but outperforms nomogram in reducing the overtreatment for the low-risk Pca.
    Wang H; Tai S; Zhang L; Zhou J; Liang C
    Cancer Manag Res; 2019; 11():3753-3763. PubMed ID: 31118794
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
    Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
    Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
    Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
    Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    Chung JW; Kim HT; Ha YS; Lee EH; Chun SY; Lee CH; Byeon KH; Choi SH; Lee JN; Kim BS; Kim TH; Yoo ES; Yoon GS; Baek MC; Kwon TG
    PLoS One; 2021; 16(4):e0250254. PubMed ID: 33901217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive model using prostate MRI findings can predict candidates for nerve sparing radical prostatectomy among low-intermediate risk prostate cancer patients.
    Song G; Ruan M; Wang H; Lin Z; Wang X; Li X; Li P; Wang Y; Zhou B; Hu X; Liu H; Wang H; Guo Y
    Transl Androl Urol; 2020 Apr; 9(2):437-444. PubMed ID: 32420149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.
    Roobol MJ; Vedder MM; Nieboer D; Houlgatte A; Vincendeau S; Lazzeri M; Guazzoni G; Stephan C; Semjonow A; Haese A; Graefen M; Steyerberg EW
    Eur Urol Focus; 2015 Sep; 1(2):185-190. PubMed ID: 28723432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.